Prenatal nutrition

Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation

Retrieved on: 
Friday, October 28, 2022
Prenatal nutrition, Diabetes, Continuous glucose monitor, Safety, Life, FreeStyle, Paganini Competition, Technology, Research, MitraClip, Nobel Prize, Film, Pharmaceutical industry, Medical device

The FreeStyle Libre system was awarded the 2019 Prix Galien USA Award for Best Medical Technology.

Key Points: 
  • The FreeStyle Libre system was awarded the 2019 Prix Galien USA Award for Best Medical Technology.
  • "The Prix Galien Golden Jubilee Awards honor the global 'best of the best' innovations that have improved the human condition over the last 50 years," said Bruno Cohen, Chairman of the Galien Foundation.
  • Over the years, Abbott has received 11 Prix Galien Awards for its innovations in pharmaceuticals and medical technology, including for Humira, MitraClipand FreeStyle Libre.
  • FreeStyle Libre 2 and FreeStyle Libre 3 systems:Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.

Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor

Retrieved on: 
Sunday, June 5, 2022
People, BGM, Life, YSI, Continuous glucose monitor, Facebook, Prenatal nutrition, Prediabetes, ADA, LinkedIn, Ageing, CGM, Category:Scientific & Academic Publishing academic journals, American Diabetes Association, FreeStyle, Statistics, Diabetes, Hypoglycemia, Patient, Comparison, Review, Reliability, T2D, NYSE, Twitter, Population, Association, Accuracy and precision, MARD, Poster, Safety, Medical device, Pharmaceutical industry

"Abbott revolutionized glucose monitoring with our world-leading FreeStyle Libre technology -- the first sensor to eliminate painful fingersticks by offering factory-calibrated continuous glucose monitoring that is affordable, accessible and accurate," said Mahmood Kazemi, M.D., divisional vice president, global medical affairs and chief medical officer of Abbott's diabetes care business. "A sub-8% overall MARD for the FreeStyle Libre 3 system is a significant milestone, not just in terms of CGM innovation, but because it empowers people with diabetes to be more confident when making important diabetes management decisions."

Key Points: 
  • The multi-centerstudy evaluated the accuracy of the FreeStyle Libre 3 system in people with type 1 or type 2 diabetes, aged 4 or older, who were on insulin therapy.
  • FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.
  • Failure to use FreeStyle Libre 3 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.
  • 1Alva S, Brazg R, Castorino K, Liljenquist D, Liu H, and Kipnes M. Performance of the FreeStyle Libre 3 System.

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System

Retrieved on: 
Friday, June 3, 2022
Consensus, Ketoacidosis, Kidney, Hospital, Life, Continuous glucose monitor, Prenatal nutrition, Diabetic ketoacidosis, DKA, Food, JDRF, CGM, Interpretation, Blood, Part, FreeStyle, Utility, Method, Journal of Diabetes Science and Technology, Risk, Review, Technology, Clinical case definition, NYSE, Pivotal, Adoption, Incidence, Diagnosis, Ketone, Heart, SGLT, CKM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Integration, Glucose, Medical device, Pharmaceutical industry, Frankincense, Fine chemical, Diabetes, Patient

"We're designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution.

Key Points: 
  • "We're designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution.
  • Recent studies show continuous ketone monitoring (CKM) could help prevent DKA.3 With continuous monitoring, rising ketone levels can be detected early, as a warning of impending ketoacidosis, and inform care so that DKA does not develop.
  • Abbott is already conducting clinical studies on the glucose-ketone monitoring system.
  • Abbott plans to partner with leading insulin pump manufacturers to make the dual monitoring system interoperable with insulin delivery systems.

Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology

Retrieved on: 
Tuesday, November 9, 2021
Quality of life, Mortality, ADA, Health education, American Diabetes Association, Healthcare disparity in Massachusetts, Color, Health, Ohio State University, Education, Health Resources and Services Administration, Technology, Diabetes, Research, Program, Partnership, Endocrinology, Awareness, Metabolism, Solution, Glucose, LinkedIn, Continuous glucose monitor, Prenatal nutrition, National Center for Integrative Biomedical Informatics, Connected for Life, NYSE, Time, FreeStyle, Life, Risk, Health equity, Pharmaceutical industry, Medical device

ABBOTT PARK, Ill. and ARLINGTON, Va., Nov. 9, 2021 /PRNewswire/ --Abbott (NYSE: ABT) and the American Diabetes Association (ADA) announced today the launch of their first joint community health partnership.

Key Points: 
  • ABBOTT PARK, Ill. and ARLINGTON, Va., Nov. 9, 2021 /PRNewswire/ --Abbott (NYSE: ABT) and the American Diabetes Association (ADA) announced today the launch of their first joint community health partnership.
  • The program seeks to better understand and address healthcare disparities for people of color living with diabetes, while fostering accessibility of diabetes care technology within the community.
  • "Diabetes is one of the most pressing health issues of our time, particularly for people of color," said Charles Henderson, chief advocacy officer of the American Diabetes Association.
  • About the American Diabetes Association:
    The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.